Top Markets
#1 ADO Protocol ADO Protocol +337.69%
#2 GoPlus Security GoPlus Security +45.51%
#3 Tutorial Tutorial +44.03%
#4 Starpower Starpower +38.64%
#5 The Black Bull The Black Bull +28.94%
#6 Nockchain Nockchain +25.82%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.07%
#8 GAIB AID GAIB AID +24.67%
#9 Fake World Assets Fake World Assets +22.34%
#10 OpenEden OpenEden +20.92%
Coin of the day
ADO Protocol ADO Protocol
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR
Kedudukan dalam Saham #34065
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Harga Saham
$0.5682
Modal Pasaran
$6.35M
Perubahan (1 hari)
-24.80%
Perubahan (1 tahun)
-57.28%
Negara
US
Perdagangan Citius Pharmaceuticals, Inc. (CTXR)

Kategori

Healthcare
Hasil untuk Citius Pharmaceuticals, Inc. (CTXR)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Citius Pharmaceuticals, Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Citius Pharmaceuticals, Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE